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Table 1. Mean (± se) number of PGP 9.5-IR nerve ﬁbres in saline, CS & ZO
treated synovial membrane
Treatment L - Non-induced (n=10) R - Induced (n=10)
Saline (n=10) 12.6±0.44ax 3.0±0.26bz
ZO (n=10) 12.2±0.38ax 11.1±0.27by
CS (n=10) 12.7±0.32ax 13.3±0.30ax
synovial membrane from the control group was heavily inﬁltrated
with inﬂammatory cells and blood vessels were abundantly found
in the subintimal layer. In contrast, synovial membrane from the
CS and ZO group had mild inﬁltration of inﬂammatory cells with
fewer blood vessels.
Conclusions: Inﬂammatory changes in the synovial membrane
from the experimentally induced joints were reduced following
supplementation of CS and ZO extracts. This was evidenced by
the histological changes. The signiﬁcant increase in the PGP 9.5
immunoreactive nerve ﬁbres in CS and ZO group shows that
these extracts have anti-inﬂammatory properties. Apart from this
CS signiﬁcantly increases the PGP 9.5-immunoreactivity with huge
reduction of inﬂammatory cells compared to ZO. This indicates that
the active component in CS plays a major role in reducing the
inﬂammatory cells and increasing the nerve ﬁbres. Therefore, CS
can be a better alternative in the treatment of osteoarthritis than
ZO.
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PROTECTION AGAINST LIPOPOLYSACCHARIDE-INDUCED
CARTILAGE INFLAMMATION AND DEGRADATION
PROVIDED BY A BIOLOGICAL EXTRACT OF MENTHA
SPICATA
W. Pearson, R. Fletcher, L. Kott, M. Hurtig
Univ. of Guelph, Guelph, ON, Canada
Purpose: The purpose of the current study was to assess the
anti-inﬂammatory and/or chondroprotective properties of Mentha
spicata (MS), purpose-bred at the University of Guelph to express
high levels of rosmarinic acid (RA), in LPS-stimulated cartilage
explants.
Methods: RA content in MS leaves was determined by HPLC.
MS was added to simulated gastric ﬂuid and simulated intestinal
ﬂuid and incubated at 37°C (7% CO2) for a total of 4 hours.
Subsequently, pH was adjusted to 7.4 and liver microsomes from
rat and NADPH were added in order to mimic metabolism of
secondary plant metabolites by the liver and incubated for an
additional 30 minutes. The resulting mixture was ultraﬁltered (50
kDa) and an aliquot analyzed for RA and its primary hepatic
metabolites (m-coumaric acid, caffeic acid, methyl rosmarinic acid
and ferulic acid). A ‘blank’ simulated digest was made using the
identical methodology but without including any MS.
Cartilage explants (4mm diameter) were excised from the articu-
lating surface of the intercarpal joint of 11 healthy pigs using a
sterile 4mm dermal biopsy tool. Explants were cultured for a total
of 96 h. Media (1000 μL) was removed from each well every 24
h. For the ﬁrst 48 h (pre-stimulation), media samples were dis-
carded. During the ﬁnal 48 h (stimulation) samples were collected
into sterile microcentrifuge tubes containing 10μg indomethacin in
DMSO.
Tissue from each animal was subjected to treatment with each
dose of MS both with and without lipopolysaccharide (LPS) stim-
ulation. For the ﬁrst 24 h of culture, tissue culture media (TCM)
contained no MS or LPS. From 24 - 96 h, TCM contained MS [0
(ie. ‘blank’), 8, 40, 80, 240, 400 μg/mL]. For the ﬁnal 48 h, explants
were exposed to an inﬂammatory stimulus (LPS; 0 or 3 μg/mL)
in order to produce an inﬂammatory state in vitro. Samples were
analyzed for PGE2(ELISA), IL-1 (ELISA), GAG (DMB), and NO
(Griess Reaction). Data were analyzed using 2-way repeated mea-
sures ANOVA with respect to treatment and time. One-way RM
ANOVA was used to detect changes in dependent variables over
time within treatments. When a signiﬁcant F-ratio was obtained,
the Holm-Sidak post-hoc test was used to detect signiﬁcantly
different means. Signiﬁcance was accepted when p<0.05.
Results: RA content of the dry leaves was 8.0% w/w. RA con-
centration in the biological extract was 49.3 μg/mL. Caffeic acid,
ferulic acid, methyl RA and m-coumaric acid were identiﬁed in the
biological extract, but were not identiﬁed in the undigested leaves.
MS inhibited LPS-induced PGE2 and NO at all doses tested. LPS-
induced GAG release from explants at a dose of 80 μg/mL, but
not at the lower or higher doses. LPS-induced IL-1 production was
not affected by MS.
Conclusions: It is concluded that MS is an effective inhibitor of
LPS-induced inﬂammation in porcine cartilage explants; this effect
may be due to its high RA content. The relative contributions of
RA and hepatic metabolites of RA are not known and are currently
under investigation.
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Purpose: Osteoarthritis (OA) is the most common form of arthri-
tis, worldwide. The underlying causes of the disease are unknown
however, the focal destruction of cartilage matrix and sclerosis
of underlying bone are thought to be the two predominant fac-
tors involved in progression of osteoarthritic disease. The most
effective treatment of OA remains the surgical removal and total
replacement of the joint (TJR) in later stages of OA. Currently,
no FDA-approved pharmacologic treatment of OA exists, particu-
larly with regard to agents that interfere with the primary structural
changes to cartilage and bone. The aims of the current study were
to test one such disease-modifying OA drug (DMOAD) candidate,
montelukast sodium in a preclinical mouse model of OA. Outcome
measures were histological scoring methods performed on mul-
tiple sections in untreated- vs. montelukast-treated OA mice to
assess potential chondroprotection and structure-modifying bone
effects offered by montelukast.
Methods: The right knees of 10 week old 129S6/SvEv male
mice were surgically induced to OA using the destabilization of
the medial meniscus (DMM). Mice were treated with montelukast
(1.5mg/Kg; qam) or carrier alone via direct intragastric delivery.
After 28 days, all knees were harvested intact & histologically
processed into 6 μm coronal sections yielding 15-20 sections per
knee. Sections were stained (Safranin-O) and scored by 3 blinded
observers using a modiﬁcation of an osteoarthritis scoring system.
Scores were analyzed using a mean maximal score representing
the highest scores for each knee, as well as a mean summed
score representing the sum of all scores within a single knee. All
scores were averaged across observers and all animals within -/+
treatment groups. Statistical signiﬁcance was analyzed using the
Kruskal-Wallis test.
Results: The mean maximal score for the montelukast-treated
OA mice (Fig. 1) was reduced by 57%. The mean summed score
(Fig. 2) which represents a combined score of OA grade and
stage was reduced by 43%. Direct morphometric measurements
of MKS-treated OA (Fig. 3) showed a 42% reduction in average
lesion area. Surprisingly, morphometric analysis of the subchon-
dral bone area (Fig. 3) showed a 9% (medial) and 8% (lateral)
decrease in OA-induced bony sclerosis with montelukast treat-
ment. This latter ﬁnding was unexpected but could represent an
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Figure 1. Effect of Montelukast treatment on Mean Maximal Knee OA Score (±
SEM).
Figure 2. Effect of Montelukast treatment on Mean Summed Knee OA Score (±
SEM).
Figure 3. Reversal of sclerotic changes in subchondral bone with Montelukast
(MKS) treatment. *p-value <0.005, **p-value <0.05.
indirect effect of decreased cartilage damage on aberrant bone re-
modeling.
Conclusions: The dual goals of translation research are to dis-
cover novel disease mechanisms and to transform this informa-
tion into new therapeutics for human disorders. Here we present
data that implicate cysteinyl leukotrienes in early OA progression.
Therefore, targeting of this pathway could represent an important
area to OA research and treatment. In addition, the apparent
similarities of the DMM model to humans at risk for OA from
meniscal damage, suggests that treatment proximal to the time
of meniscal repair with CysLT antagonists could delay the struc-
tural progression of incipient OA. Subchondral bony sclerosis is a
contributing co-factor in OA progression. Although, the reduction
in cartilage damage observed in this study could be seen as
the most clinically relevant outcome for montelukast treatment of
OA, prevention of abnormal bone remodeling could have equally
important outcomes in OA joint prophylaxis.
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Purpose: There is increasing evidence that subchondral bone
remodeling may contribute to the pathogenesis of OA, in both dis-
ease initiation and progression. In this study, we investigated the
potential role of cathepsin K (CatK) as a disease-modifying target
in the rabbit anterior cruciate ligament transection (ACLT) model
of osteoarthritis. To test the hypothesis, we evaluated the dis-
ease modifying effects of two different bone resorption inhibitors,
L-006235, a potent inhibitor of Cat K, and compared to the bis-
phosphonate Alendronate (ALN), on subchondral bone integrity,
cartilage degradation, and osteophyte formation in the rabbit ACLT
model.
Methods: Male NZW rabbits (N= 35) underwent anterior cruci-
ate ligament transection (ACLT) or sham-operation in the right
knee. The animals were dosed at one-week post-surgery with
either the CatK inhibitor L-235 (10 or 50mg/kg, p.o., daily) or ALN
(0.6mg/kg/wk, s.c.) for 8 weeks treatment duration. Rabbits were
randomized and assigned into 5 groups: Sham + vehicle (V); ACLT
+ V; ACLT + ALN; ACLT + 10mg/kg L-235; ACLT + 50mg/kg L-235.
Disease progression was evaluated by modiﬁed Mankin score.
Subchondral bone volume and osteophyte area were measured
by histomorphometric analysis. Urine levels of helical peptide, a
marker for bone resorption and CTX-II, a cartilage degradation
marker were measured at 3, 5, and 7 wk-post-surgery. Immunos-
taining of CatK and TRAP staining was performed to identify cells
expressing CatK protein and osteoclasts, respectively.
Results: In the ACLT-rabbits, CatK is highly expressed in osteo-
clasts localized to the subchondral bone region of the affected
joints. CatK expression is also found to be elevated in synovial
ﬁbroblasts, macrophages, and cells in the superﬁcial region of ar-
ticular cartilage. In addition to mediating bone matrix degradation,
detection of high CatK expression in other cell types suggests that
it may also be directly responsible for cartilage ECM degradation.
Moreover, subchondral bone resorption in the tibial plateau was
signiﬁcantly increased in the ACLT-joints at 5-wk post-surgery.
Treatment with either dose of L-235 or with ALN for 8-weeks
effectively suppressed subchondral bone loss in the ACLT-joints.
Furthermore, L-235 dose-dependently reduced osteophyte inci-
dence and area. The CatK inhibitor and ALN were partially chon-
droprotective as determined by histological evaluation and type II
collagen degradation marker. L-235 at 10mg/kg, were previously
demonstrated to fully protect estrogen-deﬁciency induced bone
loss in rabbits. While this dose of L-235 provided no chondropro-
tective effects as determined by Mankin score, 50mg/kg L-235 and
ALN provided 48% (p<0.001) and 46% (p<0.001) chondroprotec-
tion, respectively. L-235 and ALN both inhibited osteophyte forma-
tion by 56% (p<0.001) and 38% (p<0.001), respectively. TRAP
staining multinuclear cells were positive for CatK immunostaining,
and these cells were observed in subchondral region of ACLT
joint. Interestingly, in L-235-treated joint, TRAP(+) cells were small
and number of nuclei was low.
Conclusions: Taken together, the data from this study support the
important role of subchondral bone remodeling in the pathogenesis
of OA in preclinical models. Furthermore, an oral, potent and
selective CatK inhibitor may present an effective disease modifying
therapy for the treatment of osteoarthritis.
